Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas

Lenalidomide in Diffuse Large B-Cell Lymphomas

Diffuse Large B-cell Lymphomas (DLBCL) are the most frequent Non-Hodgkin Lymphomas (NHL). The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients, but so far 40% of patients experienced relapse or progressive disease. Lenalidomide, an immunomodulatory agent, had direct tumoricidal and antiangiogenetic actions on tumor cells and was able to modulate tumo...

Micro-classifying diffuse large B-cell lymphomas.

Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, with the greatest challenge for improving patient survival being the management of chemorefractory disease upon relapse. Epigenetic dysregulation has been correlated with more-aggressive malignancies and chemoresistance. In this issue of Cancer Discovery, Clozel and colleagues show the potential for low-dose ...

Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment

Diffuse large B-cell lymphomas (DLBCLs) are the most common and aggressive type of all the lymphomas. B cell lymphoma 6 (BCL6) oncogene is highly expressed in DLBCLs and one of the major reasons of treatment failure. Recent findings suggest that specific BCL6 inhibitor (FX1) disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, that in-turn suppressed growth of DLBC...

Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?

Enhancer of Zeste Homolog 2 (EZH2) plays an essential epigenetic role in Diffuse Large B Cell Lymphoma (DLBCL) development. Recurrent somatic heterozygous gain-of-function mutations of EZH2 have been identified in DLBCL, most notably affecting tyrosine 641 (Y641), inducing hyper-trimethylation of H3K27 (H3K27me3). Novel EZH2 inhibitors are being tested in phase 1 and 2 clinical trials but no st...